You are here

P&T News

May 22

President leans toward dumping insurer subsidies
Snail-paced regulators get up to Silicon Valley speed
Analyst gives treatment 50/50 chance of coming to market

May 19

Approval marks the fifth type of cancer for which the drug is indicated
Researchers analyzed data from large studies that included more than 800,000 men
Use of in vitro assay data could potentially apply to other medications
The AGs hope to prevent cuts in subsidy payments to insurance companies
Finding could lead to the first broadly effective ebolavirus therapies and vaccines

May 18

After 56 weeks of treatment with Saxenda, 91.7% of early responders maintained or lost additional weight
Agreement aims to make all outcomes—even if negative—“more findable, accessible, and reusable”
Drug demonstrated clinically meaningful results with infrequent subcutaneous administration
Median and five-year relative survival is improving, especially for those younger than age 50

May 17

Data show medications nearly doubled the chances of leg and foot amputations
Investigational compound previously received an orphan drug designation
CDC recommends retesting for certain children, pregnant women, and nursing mothers
Though hurdles remain, company plans to file a biologics license application soon
If used nationwide, “billions of dollars” in health care costs could be avoided